Dr. Catherine Daly, GlobalData’s analyst covering neurology and ophthalmology, said: “The global AMD treatment market is overwhelmingly dominated by anti-vascular endothelial growth factor (anti-VEGF) drugs, including Lucentis, Avastin, and Eylea, which together accounted for 98 per cent of sales for AMD in 2013… the anti-VEGF monopoly is set to take a dramatic tumble due to the launch of novel adjunctive therapies for wet AMD, Fovista (undergoing Phase III development) and squalamine, and the introduction of two therapies for dry AMD, lampalizumab and emixustat, during the forecast period. These entrants will cause the anti-VEGFs’ stronghold on the market to drop to 64 per cent by 2023.
*PharmaPoint: Macular Edema and Macular Degeneration – Global Drug Forecast and Market Analysis to 2023. Visit www.globaldata.com
